Company intelligence / Profile preview
KinoTeck Therapeutics Co., Ltd
Guangdong Sheng, Chinapmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
KinoTeck Therapeutics is a private Chinese biotech company focused on developing small molecule therapies targeting cancer. Its lead program, KNT-0916, is an FGFR2 inhibitor currently in Phase I clinical trials for FGFR2-altered solid tumors. Another program, BW-710, also targets FGFR2 and is in preclinical development for neoplasms. The company has also disclosed research into RSK-2 and WRN inhibitors as potential cancer therapeutics[1][4][6].
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesChemical drugs
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on KinoTeck Therapeutics Co., Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KinoTeck Therapeutics Co., Ltd.